ProMIS Neurosciences, Inc. (PMN)

ProMIS Neurosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	0
Revenue Growth (YoY)	-	-	-	-	30.20%
Cost of Revenue	-	7.88	16.09	4.63	3.18
Gross Profit	-	-7.88	-16.09	-4.63	-3.18
Selling, General & Admin	6.19	5.58	5.99	3.66	2.48
Research & Development	10.64	-	-	-	-
Operating Expenses	16.83	5.58	5.99	3.66	2.48
Operating Income	-16.83	-13.46	-22.08	-8.29	-5.66
Interest Expense	-0.08	-0.2	-0.28	-0.42	-
Interest & Investment Income	-	-	-	-	0
Other Non Operating Income (Expenses)	19.68	1.25	4.29	-1.08	-
EBT Excluding Unusual Items	2.78	-12.41	-18.07	-9.79	-5.66
Other Unusual Items	-	-0.8	0.01	-	-
Pretax Income	2.78	-13.21	-18.06	-9.79	-5.66
Net Income	2.78	-13.21	-18.06	-9.79	-5.66
Net Income to Common	2.78	-13.21	-18.06	-9.79	-5.66
Shares Outstanding (Basic)	26	12	8	6	5
Shares Outstanding (Diluted)	26	12	8	6	5
Shares Change (YoY)	115.26%	63.85%	29.68%	21.55%	9.93%
EPS (Basic)	0.11	-1.07	-2.41	-1.69	-1.19
EPS (Diluted)	0.11	-1.07	-2.41	-1.69	-1.19
Free Cash Flow	-27.18	-10.84	-17.04	-9.31	-4.46
Free Cash Flow Per Share	-1.03	-0.88	-2.27	-1.61	-0.94
Operating Margin	-	-	-	-	-361828.37%
Profit Margin	-	-	-	-	-361814.18%
Free Cash Flow Margin	-	-	-	-	-285199.36%
EBITDA	-16.81	-13.44	-22.07	-8.25	-5.65
D&A For EBITDA	0.02	0.02	0.01	0.05	0.02
EBIT	-16.83	-13.46	-22.08	-8.29	-5.66
Revenue as Reported	-	-	-	-	0

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q